1,251 results on '"Ndrepepa, Gjin"'
Search Results
102. Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis: Restenosis characteristics and clinical outcomes
103. Microvascular obstruction in patients with non-ST-elevation myocardial infarction: a contrast-enhanced cardiac magnetic resonance study
104. Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease
105. Research update for articles published in EJCI in 2013
106. Grado de perfusión miocárdica, índices de rescate miocárdico y mortalidad a largo plazo en pacientes con infarto agudo de miocardio y restablecimiento completo del flujo sanguíneo epicárdico tras intervención coronaria percutánea primaria
107. Myocardial Perfusion Grade, Myocardial Salvage Indices and Long-Term Mortality in Patients With Acute Myocardial Infarction and Full Restoration of Epicardial Blood Flow After Primary Percutaneous Coronary Intervention
108. Peak Cardiac Troponin-T Level, Scintigraphic Myocardial Infarct Size and One-Year Prognosis in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
109. Bleeding After Percutaneous Coronary Intervention With Bivalirudin or Unfractionated Heparin and One-Year Mortality
110. Prognostic value of haemoglobin drop in patients with acute coronary syndromes
111. Primary PCI, Late Presenting STEMI, and the Limits of Time
112. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate
113. Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial
114. Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis
115. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease
116. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention
117. Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis
118. Procedure-related bleeding in elective percutaneous coronary interventions
119. Stents liberadores de fármacos frente a stents convencionales en pacientes diabéticos con infarto agudo de miocardio con elevación del segmento ST: un análisis combinado de los datos de pacientes individuales de 7 ensayos aleatorizados
120. Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: A Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI)
121. Predictors of mortality in medically treated patients with congestive heart failure of nonrheumatic etiology and reduced systolic function
122. Drug-Eluting Stents Versus Bare-Metal Stents in Diabetic Patients With ST-Segment Elevation Acute Myocardial Infarction: A Pooled Analysis of Individual Patient Data From 7 Randomized Trials
123. Prognostic Value of Kidney Function in Patients With ST-Elevation and Non–ST-Elevation Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention
124. Serum potassium levels on admission and infarct size in patients with acute myocardial infarction
125. P2Y12 inhibitor intensity de-escalation in patients with acute coronary syndromes.
126. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
127. Association of coronary atherosclerotic burden with clinical presentation and prognosis in patients with stable and unstable coronary artery disease
128. Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI)
129. Association of midregional proadrenomedullin with coronary artery stenoses, soft atherosclerotic plaques and coronary artery calcium
130. Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial
131. Prognostic Significance of Epicardial Blood Flow Before and After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes
132. Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial
133. Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease
134. Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions: Appropriateness of Including Bleeding as a Component of a Quadruple End Point
135. Effect of Abciximab on Clinical and Angiographic Restenosis in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
136. Acute Effects and Long-Term Outcome of Pulmonary Vein Isolation in Combination With Electrogram-Guided Substrate Ablation for Persistent Atrial Fibrillation
137. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease
138. One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial
139. Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention
140. Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention
141. Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy
142. Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age
143. 20 - Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial Infarction
144. Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment
145. Antithrombotic treatment in primary percutaneous coronary intervention
146. Creatine kinase and bleeding in patients with acute coronary syndromes
147. Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis
148. Aspartate aminotransferase and cardiovascular disease—a narrative review
149. Research update for articles published in EJCI in 2011
150. A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.